cdri 85-287 has been researched along with cyclin d1 in 1 studies
| Studies (cdri 85-287) | Trials (cdri 85-287) | Recent Studies (post-2010) (cdri 85-287) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 22 | 0 | 3 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blesson, CS; Chandra, V; Dwivedi, A; Fatima, I; Hajela, K; Hussain, MK; Kharkwal, G; Roy, BG; Saxena, R | 1 |
1 other study(ies) available for cdri 85-287 and cyclin d1
| Article | Year |
|---|---|
Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzopyrans; Binding, Competitive; Biomarkers, Tumor; Breast Neoplasms; Cell Cycle Checkpoints; Cell Proliferation; Cyclin D1; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; G2 Phase Cell Cycle Checkpoints; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Mice; Phosphatidylinositol 3-Kinases; Piperidines; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Estrogen; Signal Transduction; Transcription Factor AP-1; Transcriptional Activation; Xenograft Model Antitumor Assays | 2013 |